

# Stephen I Deutsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11669097/publications.pdf>

Version: 2024-02-01

147  
papers

3,907  
citations

109321

35  
h-index

168389

53  
g-index

147  
all docs

147  
docs citations

147  
times ranked

3464  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted NMDA Receptor Interventions for Autism: Developmentally Determined Expression of GluN2B and GluN2A-Containing Receptors and Balanced Allosteric Modulatory Approaches. <i>Biomolecules</i> , 2022, 12, 181.	4.0	10
2	Psychotropic medication use for adults and older adults with intellectual disability; selective review, recommendations and future directions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110017.	4.8	16
3	A De Novo Missense Variant of SCN2A: Implications and Limitations for Understanding Clinical Phenotype and Treatment Recommendations. <i>Clinical Neuropharmacology</i> , 2021, 44, 138-140.	0.7	0
4	Perineuronal Nets and Metal Cation Concentrations in the Microenvironments of Fast-Spiking, Parvalbumin-Expressing GABAergic Interneurons: Relevance to Neurodevelopment and Neurodevelopmental Disorders. <i>Biomolecules</i> , 2021, 11, 1235.	4.0	13
5	Disrupted copper homeostasis: Pathogenic factor in autism spectrum disorder and side effect of valproic acid. <i>Personalized Medicine in Psychiatry</i> , 2021, 29-30, 100087.	0.1	1
6	An Evolving Therapeutic Rationale for Targeting the $\alpha 7$ Nicotinic Acetylcholine Receptor in Autism Spectrum Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 45, 167-208.	1.7	18
7	Glycine transporter type 1 (GlyT1) inhibition improves conspecific-provoked immobility in BALB/c mice: Analysis of corticosterone response and glucocorticoid gene expression in cortex and hippocampus. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109869.	4.8	7
8	Understanding facial expressivity in autism spectrum disorder: An inside out review of the biological basis and clinical implications. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 88, 401-417.	4.8	9
9	Sexuality in the Autism Spectrum Study (SASS): Reports from Young Adults and Parents. <i>Journal of Autism and Developmental Disorders</i> , 2019, 49, 3638-3655.	2.7	33
10	Collaborative interdisciplinary approaches for a heterogeneous group of neurodevelopmental disorders; A "Way" forward!. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 93, 122-123.	4.8	0
11	Metabotropic functions of the NMDA receptor and an evolving rationale for exploring NR2A-selective positive allosteric modulators for the treatment of autism spectrum disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 90, 142-160.	4.8	22
12	Neuromotor and cognitive responses of adults with autism spectrum disorder compared to neurotypical adults. <i>Experimental Brain Research</i> , 2018, 236, 2321-2332.	1.5	31
13	Autism presenting in the context of a genetic variant of CFTR and early HSV exposure confounded by chronic pain, altered gut microbiota and paternal abandonment; limitations of current pharmacotherapy and barriers to personalized treatment recommendations. <i>Personalized Medicine in Psychiatry</i> , 2017, 3, 24-29.	0.1	5
14	Sugarcoated Perineuronal Nets Regulate $\alpha$ -GABAergic Transmission: Bittersweet Hypothesis in Autism Spectrum Disorder. <i>Clinical Neuropharmacology</i> , 2017, 40, 120-130.	0.7	15
15	Experimental Assessment of Mouse Sociability Using an Automated Image Processing Approach. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	0
16	Age-dependent effects on social interaction of NMDA GluN2A receptor subtype-selective antagonism. <i>Brain Research Bulletin</i> , 2016, 125, 159-167.	3.0	7
17	Characterization of gait and olfactory behaviors in the Balb/c mouse model of autism spectrum disorders. <i>Brain Research Bulletin</i> , 2016, 122, 29-34.	3.0	5
18	Endocannabinoids and disrupted synchronous oscillations in autism spectrum disorders. <i>Future Neurology</i> , 2016, 11, 227-230.	0.5	1

#	ARTICLE	IF	CITATIONS
19	The 15q13.3 deletion syndrome: Deficient $\alpha 7$ -containing nicotinic acetylcholine receptor-mediated neurotransmission in the pathogenesis of neurodevelopmental disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 109-117.	4.8	36
20	A Trial of D-Cycloserine to Treat the Social Deficit in Older Adolescents and Young Adults With Autism Spectrum Disorders. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 133-138.	1.8	32
21	NMDA receptor activation regulates sociability by its effect on mTOR signaling activity. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 60, 60-65.	4.8	47
22	The $\alpha 7$ nicotinic acetylcholine receptor: A mediator of pathogenesis and therapeutic target in autism spectrum disorders and Down syndrome. <i>Biochemical Pharmacology</i> , 2015, 97, 363-377.	4.4	22
23	Effects of VU0410120, a novel GlyT1 inhibitor, on measures of sociability, cognition and stereotypic behaviors in a mouse model of autism. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 61, 10-17.	4.8	18
24	NMDA agonists for autism spectrum disorders: progress and possibilities. <i>Future Neurology</i> , 2015, 10, 485-500.	0.5	9
25	A Trial of D-Cycloserine to Treat Stereotypies in Older Adolescents and Young Adults With Autism Spectrum Disorder. <i>Clinical Neuropharmacology</i> , 2014, 37, 69-72.	0.7	58
26	Safety of Paliperidone Extended-Release in Patients with Schizophrenia or Schizoaffective Disorder and Hepatic Disease. <i>Clinical Schizophrenia and Related Psychoses</i> , 2014, 8, 8-20.	1.4	15
27	NMDA receptors on the surface of cancer cells: Target for chemotherapy?. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 493-496.	5.6	54
28	Rapamycin improves sociability in the BTBR T+Itpr3/J mouse model of autism spectrum disorders. <i>Brain Research Bulletin</i> , 2014, 100, 70-75.	3.0	62
29	Targeting the $\alpha 7$ nicotinic acetylcholine receptor to prevent progressive dementia and improve cognition in adults with Down's syndrome. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 54, 131-139.	4.8	28
30	Nicotinic Acetylcholine Receptors in Autism Spectrum Disorders: Therapeutic Implications. , 2014, , 755-777.		5
31	d-Cycloserine improves sociability in the BTBR T+ Itpr3tf/J mouse model of autism spectrum disorders with altered Ras/Raf/ERK1/2 signaling. <i>Brain Research Bulletin</i> , 2013, 96, 62-70.	3.0	49
32	Balb/c mice treated with d-cycloserine arouse increased social interest in conspecifics. <i>Brain Research Bulletin</i> , 2013, 99, 95-99.	3.0	26
33	Neural basis of implicit memory for socio-emotional information in schizophrenia. <i>Psychiatry Research</i> , 2013, 206, 173-180.	3.3	6
34	Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy. <i>Schizophrenia Research</i> , 2013, 148, 138-144.	2.0	68
35	Clinical Outcomes of Mild Isolated Cerebral Ventriculomegaly in the Presence of Other Neurodevelopmental Risk Factors. <i>Journal of Ultrasound in Medicine</i> , 2013, 32, 1933-1938.	1.7	10
36	Mouse models have limitations for development of medications for autism spectrum disorders, but also show much promise. <i>Future Neurology</i> , 2012, 7, 1-4.	0.5	7

#	ARTICLE	IF	CITATIONS
37	d-cycloserine improves sociability and spontaneous stereotypic behaviors in 4-week old mice. <i>Brain Research</i> , 2012, 1439, 96-107.	2.2	48
38	d-Cycloserine improves the impaired sociability of the Balb/c mouse. <i>Brain Research Bulletin</i> , 2011, 84, 8-11.	3.0	37
39	D-serine improves dimensions of the sociability deficit of the genetically-inbred Balb/c mouse strain. <i>Brain Research Bulletin</i> , 2011, 84, 12-16.	3.0	31
40	d-Cycloserine enhances social exploration in the Balb/c mouse. <i>Brain Research Bulletin</i> , 2011, 85, 141-144.	3.0	23
41	Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: Possible implications for the pharmacotherapy of autism spectrum disorders. <i>Brain Research Bulletin</i> , 2011, 86, 152-158.	3.0	59
42	Selective mGluR5 antagonism attenuates the stress-induced reduction of MK-801's antiseizure potency in the genetically inbred Balb/c mouse. <i>Epilepsy and Behavior</i> , 2011, 21, 352-355.	1.7	3
43	Selective Cyclodextrin Inhibition of Alfaxolone-induced Ataxia. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 48, 529-531.	2.4	0
44	Genetically inbred Balb/c mice differ from outbred Swiss Webster mice on discrete measures of sociability: relevance to a genetic mouse model of autism spectrum disorders. <i>Autism Research</i> , 2011, 4, 393-400.	3.8	35
45	Pharmacotherapeutic Implications of the Association Between Genomic Instability at Chromosome 15q13.3 and Autism Spectrum Disorders. <i>Clinical Neuropharmacology</i> , 2011, 34, 203-205.	0.7	20
46	Cholinergic Abnormalities in Autism. <i>Clinical Neuropharmacology</i> , 2010, 33, 114-120.	0.7	81
47	Attention to gaze and emotion in schizophrenia.. <i>Neuropsychology</i> , 2010, 24, 711-720.	1.3	14
48	Cerebral Ventricular Asymmetry and Ventriculomegaly Interact to Increase Risk for Schizophrenia: A Case Report and Recommendation for Routine Fetal Sonography. <i>CNS Spectrums</i> , 2010, 15, 574-578.	1.2	3
49	Locomotor activity of the genetically inbred Balb/c mouse strain is suppressed by a socially salient stimulus. <i>Brain Research Bulletin</i> , 2010, 83, 255-256.	3.0	24
50	MK-801, a noncompetitive NMDA receptor antagonist, elicits circling behavior in the genetically inbred Balb/c mouse strain. <i>Brain Research Bulletin</i> , 2010, 83, 337-339.	3.0	30
51	NMDA NR2B subtype-selective receptor antagonists fail to antagonize electrically-precipitated seizures and elicit popping in mice. <i>European Neuropsychopharmacology</i> , 2010, 20, 207-210.	0.7	6
52	Does subtle disturbance of neuronal migration contribute to schizophrenia and other neurodevelopmental disorders? Potential genetic mechanisms with possible treatment implications. <i>European Neuropsychopharmacology</i> , 2010, 20, 281-287.	0.7	28
53	Regulation of intermittent oscillatory activity of pyramidal cell neurons by GABA inhibitory interneurons is impaired in schizophrenia: rationale for pharmacotherapeutic GABAergic interventions. <i>Israel Journal of Psychiatry</i> , 2010, 47, 17-26.	0.2	3
54	Recognition memory probes affect what is remembered in schizophrenia. <i>Psychiatry Research</i> , 2009, 167, 21-27.	3.3	3

#	ARTICLE	IF	CITATIONS
55	Genetically inbred Balb/C mice are more sensitive to an effect of flurazepam and more resistant to an effect of stress than a genetically outbred mouse strain. <i>Epilepsy and Behavior</i> , 2009, 16, 415-417.	1.7	4
56	An epigenetic intervention interacts with genetic strain differences to modulate the stress-induced reduction of flurazepam's antiseizure efficacy in the mouse. <i>European Neuropsychopharmacology</i> , 2009, 19, 398-401.	0.7	8
57	Valproate-Induced Hyperammonemic Encephalopathy and Normal Liver Functions. <i>Clinical Neuropharmacology</i> , 2009, 32, 350-352.	0.7	50
58	Schizophrenia Endophenotypes as Treatment Targets. , 2009, , 113-122.		1
59	Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective $\alpha 7$ nicotinic acetylcholine receptor agonist strategy. <i>European Neuropsychopharmacology</i> , 2008, 18, 147-151.	0.7	11
60	Guanosine possesses specific modulatory effects on NMDA receptor-mediated neurotransmission in intact mice. <i>European Neuropsychopharmacology</i> , 2008, 18, 299-302.	0.7	17
61	Sodium butyrate, an epigenetic interventional strategy, attenuates a stress-induced alteration of MK-801's pharmacologic action. <i>European Neuropsychopharmacology</i> , 2008, 18, 565-568.	0.7	22
62	Expression of NR1, NR2A and NR2B NMDA receptor subunits is not altered in the genetically-inbred Balb/c mouse strain with heightened behavioral sensitivity to MK-801, a noncompetitive NMDA receptor antagonist. <i>European Neuropsychopharmacology</i> , 2008, 18, 814-819.	0.7	19
63	Phencyclidine and Dizocilpine Induced Behaviors Reduced by N-acetylaspartylglutamate Peptidase Inhibition via Metabotropic Glutamate Receptors. <i>Biological Psychiatry</i> , 2008, 63, 86-91.	1.3	55
64	Epigenetic Therapeutic Strategies for the Treatment of Neuropsychiatric Disorders. <i>Clinical Neuropharmacology</i> , 2008, 31, 104-119.	0.7	33
65	First Administration of Cytidine Diphosphocholine and Galantamine in Schizophrenia. <i>Clinical Neuropharmacology</i> , 2008, 31, 34-39.	0.7	31
66	Exogenously administered d-serine failed to potentiate the ability of MK-801 to antagonize electrically precipitated seizures in nonhandled control and stressed mice. <i>European Neuropsychopharmacology</i> , 2007, 17, 53-57.	0.7	3
67	Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain. <i>Brain Research Bulletin</i> , 2006, 69, 626-630.	3.0	24
68	Imitation of facial expressions in schizophrenia. <i>Psychiatry Research</i> , 2006, 145, 87-94.	3.3	33
69	Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 1369-1380.	4.8	48
70	Rare Neurodevelopmental Abnormalities of Sarcosinemia May Involve Glycinergic Stimulation of a Primed N-Methyl-d-Aspartate Receptor. <i>Clinical Neuropharmacology</i> , 2006, 29, 361-363.	0.7	6
71	Animal Models of Psychosis. <i>Contemporary Clinical Neuroscience</i> , 2006, , 193-220.	0.3	7
72	Hypothesized Deficiency of Guanine-Based Purines May Contribute to Abnormalities of Neurodevelopment, Neuromodulation, and Neurotransmission in Lesch-Nyhan Syndrome. <i>Clinical Neuropharmacology</i> , 2005, 28, 28-37.	0.7	32

#	ARTICLE	IF	CITATIONS
73	Therapeutic implications of a selective alpha7 nicotinic receptor abnormality in schizophrenia. <i>Israel Journal of Psychiatry and Related Sciences</i> , 2005, 42, 33-44.	0.5	14
74	Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia. <i>Behavioural Brain Research</i> , 2004, 153, 419-422.	2.2	35
75	Behavioral consequences of methyllycaconitine in mice: a model of $\alpha 7$ nicotinic acetylcholine receptor deficiency. <i>Life Sciences</i> , 2004, 74, 3133-3139.	4.3	22
76	The "Yoking" of glutamatergic brain mechanisms involved in controlling brain neuronal excitability and psychosis to brain mechanisms involved in appetite regulation: a new hypothesis on the origin of psychosis. <i>Medical Hypotheses</i> , 2004, 62, 406-412.	1.5	1
77	Interaction of stress and strain on glutamatergic neurotransmission: relevance to schizophrenia. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 74, 351-356.	2.9	21
78	Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent. <i>Life Sciences</i> , 2003, 73, 2355-2361.	4.3	18
79	Adjuvant Topiramate Administration: A Pharmacologic Strategy for Addressing NMDA Receptor Hypofunction in Schizophrenia. <i>Clinical Neuropharmacology</i> , 2003, 26, 199-206.	0.7	33
80	Methyllycaconitine Fails to Inhibit Electrically Precipitated Tonic Hindlimb Extension in Mice. <i>Clinical Neuropharmacology</i> , 2003, 26, 62-64.	0.7	2
81	Progressive Worsening of Adaptive Functions in Down Syndrome May Be Mediated By the Complexing of Soluble $A\beta$ Peptides With the $\alpha 7$ Nicotinic Acetylcholine Receptor: Therapeutic Implications. <i>Clinical Neuropharmacology</i> , 2003, 26, 277-283.	0.7	18
82	Implicit learning of visuospatial sequences in schizophrenia.. <i>Neuropsychology</i> , 2003, 17, 517-533.	1.3	49
83	Adjuvant Galantamine Administration Improves Negative Symptoms in a Patient With Treatment-Refractory Schizophrenia. <i>Clinical Neuropharmacology</i> , 2002, 25, 272-275.	0.7	63
84	Configural processing in face recognition in schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2002, 7, 15-39.	1.3	48
85	Topiramate antagonizes MK-801 in an animal model of schizophrenia. <i>European Journal of Pharmacology</i> , 2002, 449, 121-125.	3.5	45
86	A Revised Excitotoxic Hypothesis of Schizophrenia: Therapeutic Implications. <i>Clinical Neuropharmacology</i> , 2001, 24, 43-49.	0.7	135
87	Topiramate Improves Deficit Symptoms in a Patient with Schizophrenia when Added to a Stable Regimen of Antipsychotic Medication. <i>Clinical Neuropharmacology</i> , 2001, 24, 290-294.	0.7	31
88	Nefazodone in the Adjunctive Therapy of Schizophrenia: An Open-Label Exploratory Study. <i>Clinical Neuropharmacology</i> , 2000, 23, 222-225.	0.7	10
89	Visual Scanning of Facial Expressions in Schizophrenia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999, 11, 103-106.	1.8	22
90	Both nicotine and mecamylamine block dizocilpine-induced explosive jumping behavior in mice: psychiatric implications. <i>Psychopharmacology</i> , 1998, 140, 202-205.	3.1	22

#	ARTICLE	IF	CITATIONS
91	Behavioral Approaches to the Functional Assessment of NMDA-Mediated Neural Transmission in Intact Mice. <i>Clinical Neuropharmacology</i> , 1997, 20, 375-384.	0.7	32
92	Histamine H2 Receptor Antagonists in Schizophrenia. <i>CNS Drugs</i> , 1997, 8, 276-284.	5.9	7
93	Inbred Mouse Strains Differ in Sensitivity to "Popping" Behavior Elicited by MK-801. <i>Pharmacology Biochemistry and Behavior</i> , 1997, 57, 315-317.	2.9	48
94	Impaired motor skill learning in schizophrenia: implications for corticostriatal dysfunction. <i>Biological Psychiatry</i> , 1996, 39, 241-248.	1.3	50
95	An Open-Label Study of the Therapeutic Efficacy of High-Dose Famotidine Adjuvant Pharmacotherapy in Schizophrenia: Preliminary Evidence for Treatment Efficacy. <i>Clinical Neuropharmacology</i> , 1996, 19, 341-348.	0.7	31
96	D-Cycloserine Adjuvant Therapy to Molindone in the Treatment of Schizophrenia. <i>Clinical Neuropharmacology</i> , 1996, 19, 444-450.	0.7	52
97	Famotidine Adjunctive Pharmacotherapy of Schizophrenia. <i>Clinical Neuropharmacology</i> , 1995, 18, 369-374.	0.7	16
98	Computerized Measurement of MK-801-Elicited Popping and Hyperactivity in Mice. <i>Clinical Neuropharmacology</i> , 1995, 18, 448-457.	0.7	28
99	MK-801 alters the GABAA receptor complex and potentiates flurazepam's antiseizure efficacy. <i>Pharmacology Biochemistry and Behavior</i> , 1995, 51, 909-915.	2.9	12
100	Anxiety and pupil reactivity in cocaine dependent subjects endorsing cocaine-induced paranoia: preliminary report. <i>Addiction</i> , 1995, 90, 981-984.	3.3	3
101	The effects of adenosine A3 receptor stimulation on seizures in mice. <i>European Journal of Pharmacology</i> , 1995, 275, 23-29.	3.5	86
102	A glycinergic intervention potentiates the antiseizure efficacies of MK-801, flurazepam, and carbamazepine. <i>Neurochemical Research</i> , 1994, 19, 161-165.	3.3	17
103	Allosteric effects of a GABA receptor-active steroid are altered by stress. <i>Pharmacology Biochemistry and Behavior</i> , 1994, 47, 913-917.	2.9	13
104	The relationship between cocaine-induced paranoia and compulsive foraging: a preliminary report. <i>Addiction</i> , 1994, 89, 1097-1104.	3.3	63
105	Saccadic distractibility in cocaine dependent patients: A preliminary laboratory exploration of the cocaine-OCD hypothesis. <i>Drug and Alcohol Dependence</i> , 1994, 35, 25-30.	3.2	18
106	Environmental Stress-Induced Functional Modification of the Central Benzodiazepine Binding Site. <i>Clinical Neuropharmacology</i> , 1994, 17, 205-228.	0.7	23
107	Phenomenologic Comparison of the Idiopathic Psychosis of Schizophrenia and Drug-Induced Cocaine and Phencyclidine Psychoses. <i>Clinical Neuropharmacology</i> , 1994, 17, 359-369.	0.7	49
108	Discriminative stimulus properties of midazolam are shared by a GABA-receptor positive steroid. <i>Pharmacology Biochemistry and Behavior</i> , 1993, 46, 963-965.	2.9	17

#	ARTICLE	IF	CITATIONS
109	Swim stress selectively alters the specific binding of a benzodiazepine antagonist in mice. <i>Pharmacology Biochemistry and Behavior</i> , 1993, 45, 299-304.	2.9	16
110	Limits of the processing view in accounting for dissociations among memory measures in a clinical population. <i>Memory and Cognition</i> , 1993, 21, 63-72.	1.6	101
111	Measures of visual scanning as a predictor of cocaine cravings and urges. <i>Biological Psychiatry</i> , 1993, 33, 554-556.	1.3	28
112	Measurement of an Explosive Behavior in the Mouse, Induced by MK-801, a PCP Analogue. <i>Clinical Neuropharmacology</i> , 1993, 16, 251-257.	0.7	32
113	Positive and Negative Symptoms of Schizophrenia as Predictors of Length of Military Service: A Retrospective Study. <i>Military Medicine</i> , 1993, 158, 529-533.	0.8	1
114	GABA-Active Steroids. <i>Clinical Neuropharmacology</i> , 1992, 15, 352-364.	0.7	69
115	Reduction of flurazepam's antiseizure efficacy persists after stress. <i>Pharmacology Biochemistry and Behavior</i> , 1992, 42, 681-684.	2.9	6
116	Effects of milacemide, a glycine prodrug, on ethanol's antiseizure efficacy. <i>Pharmacology Biochemistry and Behavior</i> , 1992, 41, 263-266.	2.9	4
117	Paradoxical effect of flurazepam. <i>Pharmacology Biochemistry and Behavior</i> , 1992, 42, 517-518.	2.9	1
118	Glycinergic interventions potentiate the ability of MK 801 to raise the threshold voltage for tonic hindlimb extension in mice. <i>Pharmacology Biochemistry and Behavior</i> , 1992, 43, 609-612.	2.9	17
119	Ethanol's antiseizure efficacy is reduced by stress. <i>Pharmacology Biochemistry and Behavior</i> , 1992, 41, 663-664.	2.9	3
120	Subtype diagnosis in schizophrenia and its relation to neuropsychological and computerized tomography measures. <i>Biological Psychiatry</i> , 1991, 30, 63-72.	1.3	25
121	Memory for temporal order in Schizophrenia. <i>Biological Psychiatry</i> , 1991, 29, 329-339.	1.3	79
122	An NMDA Intervention Strategy in Schizophrenia With "Low-Dose" Milacemide. <i>Clinical Neuropharmacology</i> , 1991, 14, 268-272.	0.7	36
123	Potentiation of ethanol via interference with calcium channels. <i>Pharmacology Biochemistry and Behavior</i> , 1991, 38, 665-668.	2.9	6
124	An Open-Label Trial of Milacemide in Schizophrenia. <i>Clinical Neuropharmacology</i> , 1990, 13, 348-354.	0.7	31
125	Interaction of cholinergic and glutamatergic transmission in the hippocampus: An in vitro autoradiographic receptor analysis. <i>Neuroscience Letters</i> , 1990, 118, 124-127.	2.1	6
126	Adrenalectomy prevents the stress-induced decrease in in vitro [ <sup>3</sup> H]Ro15-1788 binding to GABA <sub>A</sub> benzodiazepine receptors in the mouse. <i>Brain Research</i> , 1990, 519, 347-350.	2.2	41

#	ARTICLE	IF	CITATIONS
127	Profound stress-induced alterations in flurazepam's antiseizure efficacy can be attenuated. <i>Brain Research</i> , 1990, 520, 272-276.	2.2	25
128	Biological Studies of Attention-Deficit Disorder. , 1990, , 231-239.		2
129	Role of the GABA $\alpha$ Benzodiazepine Receptor Complex in Stress. , 1990, , 61-76.		1
130	Neuroendocrine Abnormalities in Autism and Schizophrenic Disorder of Childhood. , 1990, , 153-160.		0
131	Novel Drug Development in the Developmental Disorders. , 1990, , 369-382.		0
132	A $\alpha$ -Glutamatergic Hypothesis of Schizophrenia. <i>Clinical Neuropharmacology</i> , 1989, 12, 1-13.	0.7	239
133	Glycine Adjuvant Therapy to Conventional Neuroleptic Treatment in Schizophrenia. <i>Clinical Neuropharmacology</i> , 1989, 12, 416-424.	0.7	92
134	The Role of Excitatory Amino Acids and Intraneuronal Calcium in the Acute Intoxicational Effects of Ethanol. <i>Clinical Neuropharmacology</i> , 1989, 12, 483-489.	0.7	6
135	Glutamatergic Abnormalities in Alzheimer's Disease and a Rationale for Clinical Trials with L-Glutamate. <i>Clinical Neuropharmacology</i> , 1988, 11, 18-35.	0.7	35
136	Rapid increase in brain benzodiazepine receptor binding following defeat stress in mice. <i>Brain Research</i> , 1987, 414, 395-400.	2.2	111
137	Cholinesterase activities in blood in infantile autism. <i>Biological Psychiatry</i> , 1987, 22, 234-236.	1.3	4
138	Benzodiazepine Receptor Binding of Triazolobenzodiazepines In Vivo: Increased Receptor Number with Low-Dose Alprazolam. <i>Journal of Neurochemistry</i> , 1987, 49, 1595-1601.	3.9	33
139	Relative Affinities for Different Classes of Neurotransmitter Receptors Predict Neuroleptic Efficacy in Infantile Autism: a Hypothesis. <i>Neuropsychobiology</i> , 1986, 15, 160-164.	1.9	5
140	Plasma growth hormone response to insulin-induced hypoglycemia in infantile autism: A pilot study. <i>Journal of Autism and Developmental Disorders</i> , 1986, 16, 59-68.	2.7	11
141	Plasma growth hormone response to oral l-dopa in infantile autism. <i>Journal of Autism and Developmental Disorders</i> , 1985, 15, 205-212.	2.7	17
142	Status of cholinesterase activities in blood in neuropsychiatric disorders. <i>Neurochemical Research</i> , 1984, 9, 863-869.	3.3	15
143	Schizophrenia: A Review of Diagnostic and Biological Issues I. Diagnosis and Prognosis. <i>Psychiatric Services</i> , 1983, 34, 313-322.	2.0	2
144	A rationale for studying the transmissibility of Alzheimer's disease. <i>Neurobiology of Aging</i> , 1982, 3, 145-147.	3.1	3

#	ARTICLE	IF	CITATIONS
145	Erythrocyte glycine in depressed, hypomanic, and euthymic bipolar patients treated with lithium carbonate. <i>Psychopharmacology</i> , 1982, 78, 314-316.	3.1	2
146	The effect of lithium on rat brain and erythrocyte glycine levels. <i>European Journal of Pharmacology</i> , 1981, 75, 75-76.	3.5	13
147	Regulation of growth and morphological modulation of HeLa65 cells in monolayer culture by dibutyryl cyclic AMP, butyrate and their analogs. <i>Journal of Cellular Physiology</i> , 1975, 86, 663-672.	4.1	38